Tweet
June 13, 2019
The Revival of a Forgotten Cancer Gene Therapy With Off-the-Shelf Potential
Christina Bennett, MS
A seemingly forgotten, off-the-shelf cancer gene therapy from the early 2000s appears to be getting a revival. Eight cancer patients who received the therapy a decade ago are still alive, and the features of these super responders were reported at the 2019 American Society of Gene and Cell Therapy (ASGCT) annual meeting in Washington, D.C.1,2 And now, phase 2 trials are being planned to further evaluate the therapy.
The tumor-targeted gene therapy, known as DeltaRex-G (formerly Rexin-G), works by delivering a retroviral vector to tumor cells that encodes for an anticyclin G1 construct that is meant to inhibit the cyclin G1 gene (CCNG1), leading to cell death. The first-in-human study was conducted in the Philippines in 2002 with patients who had chemotherapy-resistant solid tumors...
Comment